Thomson ReutersFile photo of the headquarters of Valeant Pharmaceuticals International Inc in Laval
However, the company reiterated that it would file the report with U.S. and Canadian regulators on or before June 10, ahead of a July 31 deadline.
Valeant has lost more than half its value since mid-March, after it said a delay in the filing of its annual report could put it at risk of a default on its borrowings.
The Laval, Quebec based company is also facing mounting scrutiny from the U.S. Congress, prosecutors and regulators over its drug pricing, business practices and accounting, issues that have pushed its shares down nearly 89 percent since August.
(Reporting by Natalie Grover in Bengaluru; Editing by Anil D’Silva)
Read the original article on Reuters. Copyright 2016. Follow Reuters on Twitter.
More from Reuters:
- Iraq SOMO head says so far, so good for OPEC’s strategy
- NATO’s Pavel denounces Trump for calling alliance ‘obsolete’
- Jobs aggregator Glassdoor raises $40 million in new financing round
- Venezuela crisis set to dominate Caribbean summit in Cuba
- Equities attract $1.5 billion, first inflows in eight weeks: BAML
Leave a Reply
Leave a Reply
This site uses Akismet to reduce spam. Learn how your comment data is processed.
